Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, controlled, multicentre trial regarding the safety and feasibility of treatment with empagliflozin compared with NPH insulin treatment in patients with newly onset diabetes following initiation of glucocorticoid treatment.

Next Previous
Trial Profile

A randomized, controlled, multicentre trial regarding the safety and feasibility of treatment with empagliflozin compared with NPH insulin treatment in patients with newly onset diabetes following initiation of glucocorticoid treatment.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 31 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Empagliflozin (Primary) ; Insulin
  • Indications Diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms EANITIATE

Most Recent Events

  • 28 Jan 2022 Status changed from recruiting to discontinued.
  • 10 Dec 2018 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top